Neutral sphingomyelinase mediates the co-morbidity trias of alcohol abuse, major depression and bone defects

Mol Psychiatry. 2021 Dec;26(12):7403-7416. doi: 10.1038/s41380-021-01304-w. Epub 2021 Sep 28.

Abstract

Mental disorders are highly comorbid and occur together with physical diseases, which are often considered to arise from separate pathogenic pathways. We observed in alcohol-dependent patients increased serum activity of neutral sphingomyelinase. A genetic association analysis in 456,693 volunteers found associations of haplotypes of SMPD3 coding for NSM-2 (NSM) with alcohol consumption, but also with affective state, and bone mineralisation. Functional analysis in mice showed that NSM controls alcohol consumption, affective behaviour, and their interaction by regulating hippocampal volume, cortical connectivity, and monoaminergic responses. Furthermore, NSM controlled bone-brain communication by enhancing osteocalcin signalling, which can independently supress alcohol consumption and reduce depressive behaviour. Altogether, we identified a single gene source for multiple pathways originating in the brain and bone, which interlink disorders of a mental-physical co-morbidity trias of alcohol abuse-depression/anxiety-bone disorder. Targeting NSM and osteocalcin signalling may, thus, provide a new systems approach in the treatment of a mental-physical co-morbidity trias.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alcoholism* / genetics
  • Animals
  • Bone Diseases* / genetics
  • Comorbidity
  • Depressive Disorder, Major* / genetics
  • Humans
  • Mice
  • Morbidity
  • Sphingomyelin Phosphodiesterase* / genetics

Substances

  • SMPD3 protein, human
  • Smpd3 protein, mouse
  • Sphingomyelin Phosphodiesterase